Antiprogrammed Cell Death-1 Immunotherapy-Related Secondary Sclerosing Cholangitis
Kohei Ogawa,* Kenya Kamimura , * and Shuji Terai S econdary sclerosing cholangitis (SSC) is a rare disease that is associated with various etiologies. Recent developments of immune checkpoint inhibitors demonstrate efficacy in the treatment of various malignancies; however, these inhibitors can also cause immune-related adverse events, including inflammatory manifestations. This study reports on pembrolizumab-induced SSC through imaging and histological analyses.
Case Presentation
A 73-year-old man was referred to our hospital requiring further investigation of elevated hepatobiliary enzymes. He was receiving treatment of antiprogrammed cell death-1 (PD-1) immunotherapy with pembrolizumab (2.0 mg/kg) every 3 weeks for a malignant melanoma in his left heel. Computed tomography (CT) was performed before pembrolizumab treatment ( Fig. 1A ) at the onset of cholangitis (Fig. 1B) , and 1 month after laboratory data returned to the normal range ( Fig. 1C ). No liver metastases or bile duct dilatation were observed before treatment ( Fig. 1A) . After 3 months of treatment, laboratory findings revealed mildly elevated liver and biliary enzymes, aspartate aminotransferase levels of 58 IU/L, alanine aminotransferase levels of 77 IU/L, alkaline phosphatase levels of 1,111 IU/L, and γ-glutamyl transferase levels of 461 IU/L. The patient was not on any other medications known to cause a cholestatic pattern of liver injury. CT revealed dilatation of the intrahepatic bile duct without any visible obstructions, including cholelithiasis or tumors. Thickness in the walls of the bile ducts and the gallbladder was also revealed ( Fig. 1B) . Contrast enhancement of the bile duct revealed multiple strictures and dilatations of the intrahepatic and extrahepatic bile ducts ( Fig. 1D ). Endoscopic ultrasound also revealed significant caliber fluctuations and irregular wall thickness of the intrahepatic and extrahepatic bile ducts ( Fig. 1E ). Histological findings of the bile duct wall biopsy confirmed the destruction of biliary epithelium with fibrosis under the epithelium as well as diffuse infiltration of inflammatory lymphocytes ( Fig. 2A) , particularly CD8-positive T cells ( Fig. 2B ) and plasma cells. Based on these results and the clinical course, the patient was diagnosed with SSC induced by pembrolizumab administration. The level of hepatobiliary enzymes slowly returned to the normal range 40 days after anti-PD-1 immunotherapy was discontinued without immunosuppressants (Fig. 2C ). CT confirmed recovery of biliary tract dilatation (Fig. 1C ).
Discussion
The development of immune checkpoint inhibitors, including PD-1 and programmed cell death-ligand 1, has led to a remarkable treatment response in various cancers. However, they can also cause immune-related adverse events, including colitis, dermatitis, hepatitis, endocrine manifestations, and other inflammatory and autoimmune manifestations. Recently, Johncilla et al. (1) reported 11 cases of immune-related liver diseases. Cholangitic liver diseases have also been reported, although rare. (2) These cases include avelumab (3) and nivolumab (4, 5) related cholangitis, which present similar images ( Fig. 1) and patterns of CD8-positive T-cell infiltration into the bile duct ( Fig. 2B ) as in our case, which resulted in immune-related cholangitis and a cholestatic pattern of liver injury. (1) (2) (3) (4) (5) Inflammation and destruction of the bile duct can result in SSC and lead to chronic cholestasis. (3, 4) This study reports on a patient with pembrolizumab-induced SSC. Increased hepatobiliary enzymes, caliber fluctuations, irregular wall thickness of intrahepatic and extrahepatic bile ducts, and significant infiltration of inflammatory T cells dominant in CD8-positive T cells were all observed. In our case, laboratory data recovered without administrating immunosuppressants (Fig. 2C) . However, further studies are necessary to establish the optimal management of patients with this immunotherapy-related SSC. (2, 4) These findings suggest that the possibility of SSC should be considered when administering immune checkpoint inhibitors to patients.
